



# LUND UNIVERSITY

## Diagnosis and Treatment of Common Forms of Tremor

Puschmann, Andreas; Wszolek, Zbigniew K.

*Published in:*  
Seminars in Neurology

*DOI:*  
[10.1055/s-0031-1271312](https://doi.org/10.1055/s-0031-1271312)

2011

[Link to publication](#)

*Citation for published version (APA):*

Puschmann, A., & Wszolek, Z. K. (2011). Diagnosis and Treatment of Common Forms of Tremor. *Seminars in Neurology*, 31(1), 65-77. <https://doi.org/10.1055/s-0031-1271312>

*Total number of authors:*  
2

### General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00





LUND UNIVERSITY  
Faculty of Medicine

---

# LUP

*Lund University Publications*

Institutional Repository of Lund University

---

This is an author produced version of a paper published in *Seminars in Neurology*. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Citation for the published paper:  
Andreas Puschmann, Zbigniew K. Wszolek

"Diagnosis and Treatment of Common Forms of Tremor"

*Seminars in Neurology*  
2011 31(1), 65 - 77

[www.thieme-connect.com](http://www.thieme-connect.com)

<http://dx.doi.org/10.1055/s-0031-1271312>

Access to the published version may require journal subscription.

Published with permission from: Thieme Medical Publications Ltd

Article Title:

**Diagnosis and Treatment of Common Forms of Tremor**

Authors:

Andreas Puschmann, MD, Department for Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Fl., 32224, U.S.A., Tel. 904-953-7760, Fax 904-953-0760, and Dept. for Geriatric Psychiatry, Lund University, Getingevägen 4, 221 85 Lund, Sweden, Andreas.Puschmann@med.lu.se

(Corresponding author)

Zbigniew K. Wszolek, MD, PhD, Department for Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Fl., 32224, U.S.A., Tel. 904-953-7228, Fax 904-953-0760, Wszolek.Zbigniew@mayo.edu

### Abstract:

Tremor is the most common movement disorder presenting to an outpatient neurology practice and is defined as a rhythmical, involuntary oscillatory movement of a body part. This article reviews the clinical examination, classification, and diagnosis of tremors. The pathophysiology of the more common forms of tremor is outlined, and treatment options are discussed. Essential tremor is characterized primarily by postural and action tremors, may be a neurodegenerative disorder with pathological changes in the cerebellum, and can be treated with a wide range of pharmacological and non-pharmacological methods. Tremor at rest is typical for Parkinson disease, but may arise independently of a dopaminergic deficit. Enhanced physiological tremor, intention tremor, and dystonic tremor are discussed. Further differential diagnoses described in this review include drug- or toxin-induced tremor, neuropathic tremor, psychogenic tremor, orthostatic tremor, palatal tremor, tremor in Wilson's disease, and tremor secondary to cerebral lesions, such as Holmes' tremor (midbrain tremor). An individualized approach to treatment of tremor patients is important, taking into account the degree of disability, including social embarrassment, which the tremor causes in the patient's life.

### Keywords:

*Tremor*

*Essential Tremor*

*Parkinson Disease*

*Dystonia*

*Pathophysiology*

## INTRODUCTION

Tremor is defined as a rhythmical, involuntary oscillatory movement of a body part that is produced by alternating contractions of reciprocally innervated muscles.<sup>1,2</sup> It is the most commonly encountered movement disorder symptom, and is frequently evaluated and treated in family medicine, internal medicine, emergency medicine, and of course neurology practices.<sup>3,4</sup> When assessing a patient with tremor, the phenomenology of the tremor, the presence or absence of other neurological signs or symptoms, and the possible modifying influence of medications or alcohol are important factors to be determined. The patient's history and a targeted neurological examination will usually suffice to diagnose the cause of the tremor.

A wide array of treatment modalities are available for tremor, and most depend on the type or the underlying cause of the tremor. Treatment is tailored individually, taking into account the objectively measurable tremor severity, the degree of disability or impairment experienced by the patient and in relation to the patient's activities, including embarrassment in social situations, as well as the patient's preference among the various treatment options.<sup>5</sup> The majority of patients with tremor have relatively mild symptoms and some may benefit from reassurance alone. The overall effectiveness of pharmacological treatments of tremor unfortunately remains mediocre, and patients frequently decide to discontinue such treatments. A fraction of patients with tremor have such severe symptoms that surgical procedures such as deep brain stimulation (DBS) may be necessary. This article provides the clinician with a review of the assessment, pathophysiology and treatment of the more common forms of tremor.

## PATHOPHYSIOLOGY OF TREMOR

Progress has been achieved in mapping tremors to certain structures or pathways in the nervous system, even though the exact pathophysiology of tremor is still incompletely understood. Two basic principles have been postulated in tremorogenesis. One emphasizes a functional hyperexcitability and rhythmic oscillation of neuronal loops in the absence of structural changes. This hyperexcitability has been studied with neurophysiological techniques in humans and animals, and modeled in dynamic mathematical paradigms.<sup>6</sup> Complete reversibility of some tremor symptoms after alcohol ingestion or with medication has been interpreted as evidence for an overwhelmingly or exclusively functional disturbance. The second principle is that of a permanent structural pathology with signs of neurodegeneration. This concept has more recently received renewed attention after systematic pathological studies of patients with ET revealed characteristic pathological changes.<sup>4</sup>

Two sets of neuronal networks are of particular importance (Figure 1). One is the ***cortico-striato-thalamo-cortical loop*** through the basal ganglia, whose physiological task is the integration of different muscle groups for complex movement programs. This loop also ensures that an ongoing movement program will not be terminated or disturbed by minor or irrelevant external influences. The other circuit involves the ***red nucleus, inferior olivary nucleus*** (ION) and the ***dentate nucleus***, forming the triangle of Guillain and Mollaret (Guillain-Mollaret triangle). This circuit's main physiological task is to fine-tune

voluntary precision movements. Among its components, probably the ION plays the most important role in the genesis of tremor. The neurons of the ION receive their input from the red nucleus, and project as climbing fibers to Purkinje cells in the cerebellar cortex. The individual ION neurons are connected by gap junctions and can thereby act as a synchronized neuronal ensemble.<sup>7</sup> In healthy individuals, ION neurons exhibit regular oscillatory depolarizations mediated by calcium-channels.<sup>8</sup> These oscillations serve an important physiological purpose as pacemakers in the timely processing and temporal coordination of the cerebellar modulation of precision movements as well as in cerebellar motor learning.<sup>7</sup> A line of evidence suggests that such synchronized oscillations of ION neurons also are involved in the genesis of tremor. The beta-carboline alkaloids harmine, harmaline, and tetrahydroharmine from the Harmal plant (*Peganum harmala*, 'Syrian Rue'), increase ION neuron excitability. While the seeds and roots of this plant also have hallucinogenic and antinociceptive properties, and have been used as an entheogen for many centuries,<sup>9</sup> a transient cerebellar syndrome with dysmetria and nystagmus as well as intention and postural tremor were documented after ingestion of high doses.<sup>10</sup> This effect is also seen in animals, and in fact harmaline is frequently used to model ET in animals.<sup>11</sup> In such animals, harmaline-induced tremors are abolished by lesioning the ION, emphasizing harmaline's impact on the triangle of Guillain and Mollaret.<sup>12</sup> In addition to chemical substances, structural lesions affecting this circuit can cause tremor. Lesions damaging afferents to the ION are responsible for symptomatic palatal tremor associated with reactive hypertrophic degeneration of the ION.<sup>13</sup> Hypertrophy of the ION is also seen in the rare syndrome of progressive ataxia and palatal tremor, further implicating ION in tremorogenesis.<sup>14</sup>

## **GENERAL APPROACH TO AN OUTPATIENT WITH TREMOR**

### **Tremor phenomenology, terminology and classification**

Assessment of a patient with tremor starts with the characterization of the tremor phenomenology, which narrows down the differential diagnosis and often can establish a diagnosis. Tremors can be classified according to various parameters (Table 1). The most important parameter for tremor evaluation is describing when the tremor occurs in relation to movements or position of the affected body part, distinguishing between tremor at rest (rest or resting tremor) and action tremor. This distinction helps in grouping tremors according to their pathophysiology and etiology, which in turn is highly relevant for choosing the most promising treatment option.

Tremor at rest denotes a tremor in a body part that is not voluntarily moved or maintained in a certain position against gravity, and typically occurs in Parkinson disease (PD). The other main tremor type, action tremor, includes all tremor manifestations in body parts that are not at rest, and comprises postural tremor and kinetic tremor (Table 2). In most cases, action tremor can be easily distinguished from tremor at rest. However, patients with PD may display a tremor that re-occurs when arms are maintained stretched out for some seconds (re-emerging tremor). From a physiological standpoint, this may be considered a tremor at rest, as the body part has been held motionless in this position for a period of time. Thus, tremor that re-emerges after a short period of time should not be classified as true postural tremor.

Other tremor characteristics are the location or distribution in the different body parts, the tremor frequency, the presence of exacerbating or alleviating factors, and the presence of other neurological signs or symptoms (Table 1). These characteristics are rarely specific for a certain cause of tremor. For example, essential tremor (ET) may or may not improve after alcohol ingestion, but also other types of tremor may improve with alcohol.<sup>15</sup>

### Tremor Frequency

The frequency of a tremor can be approximated by observation with the naked eye, and more accurately measured with surface electromyography. The most often encountered tremors have frequencies between 4 and 12 Hz.<sup>1</sup> Tremor in PD often has a slower frequency of between 3 and 5 Hz, and ET and enhanced physiological tremor range from 5 to 10 Hz. However, while there may be general differences in average tremor frequency among different types of tremors, the frequencies overlap considerably between different disorders. Thus, the exact determination of tremor frequency rarely adds decisive new information when the cause of a tremor in an individual patient is uncertain. Exceptions are unusually fast or slow tremor frequencies which may help to establish a correct diagnosis. Tremor frequencies below 4 Hz occur in Parkinsonian, cerebellar, Holmes', drug-induced or palatal tremors.<sup>1</sup> Primary orthostatic tremor has a high frequency of 12-18Hz.<sup>1</sup> On the other hand, the clinical appearances of these syndromes are often characteristic enough for an accurate diagnosis without measuring tremor frequency.

### Tremor Terminology

The nomenclature of tremors is not standardized and sometimes confusing, and some terms may have different meanings. Strictly speaking, the term "intention tremor" only denotes rhythmic, oscillatory movements. However, the term is also sometimes used to describe more irregular, ataxic movements. Both represent a disturbance in the fine-tuning of goal-directed movements and point towards the cerebellum or its inflow- and outflow tracts. Similarly, the expression "dystonic tremor" usually stands for arrhythmic (i.e. the intervals between the movements are not equal) and/or irregular (i.e. amplitudes vary from one movement to the next) movements that are, thus, not "tremor" according to its definition. However, we include both intention tremor and dystonic tremor in this review, as they are important differential diagnoses along with “true” tremors, and commonly referred to as “tremors”. We prefer the term "intention tremor" to "cerebellar tremor", as other types of tremor also involve the cerebellum (see below). Patients may display several types of tremor and it can be challenging to separate the single components. A general rule is to name the predominant tremor after the position in which the largest amplitude occurs. A diagnostic problem may arise when action tremor persists at rest. If an action tremor persists with the same amplitude during rest, by convention the tremor is considered action tremor.<sup>1</sup>

### **Interview and clinical examination of patients with tremor**

When assessing a patient with tremor, the type of tremor (Table 2) is characterized and other manifestations of a possible underlying neurological disorder are actively sought. A thorough neurological examination of a patient presenting with tremor includes the following parts:

Tremor at rest may be seen when observing the patient with the affected body part neither voluntarily activated nor supported against gravity. It can become more pronounced when the patient is concentrating on other tasks, e.g. when walking or during a conversation. Postural tremor that was not seen in other parts of the examination can become visible when the patient holds the upper extremities in an outstretched position with the hands supine, prone, and in the wing position (i.e., with the index fingers pointing at each other in front of the thorax but not touching). Irregular hand or finger movements in these positions are not tremor. Sudden loss of muscle tone with a sudden drop of a finger or hand, succeeded by a corrective movement back to the initial position, indicates negative myoclonus. Intention tremor is characterized by overshooting movements of increasing amplitude when approaching a goal. It can be elicited in goal-directed activities, such as finger-to-nose, heel-to-shin, and toe-to-finger movements.

Observing a patient while drawing (e.g. Archimedes spirals) or writing is often helpful. Action tremor is increased during writing or drawing, and a task-specific tremor may become obvious. In Parkinson Disease (PD), there usually is no tremor during writing, but other signs can be seen, such as increasing micrographia and slow movements. Pouring water from one cup into another shows the degree of disability due to kinetic tremor in practical situation.

Important clues about an underlying neurological disorder in patients presenting with a tremor can be found during the examination of the cranial nerves, speech, gait, balance, and muscle tone. Eye movement abnormalities may suggest cerebellar disease, and Kayser-Fleischer rings are specific for impaired copper homeostasis, although their

absence does not exclude Wilson Disease. Torticollis, blepharospasm or orofacial twitching, may indicate dystonia. These signs can be very mild, in which case the patient may not be aware of any disturbance. Several movement disorders affect the fine-tuned movements of the tongue, where possible abnormal findings include fasciculations or slowness of tongue movements. Slow and irregular speech with increased separation of syllables or explosive sounds may indicate cerebellar dysarthria. Dystonia can manifest as spasmodic dysphonia (SD), with effortful, jerky, strained sounds in the adductor type of SD, or a breathy, whispering voice with sudden breaks in the abductor type of SD. Typical Parkinsonian or cerebellar gait may be noted, and muscular rigidity in combination with a tremor at rest is typical for PD, whereas spasticity may develop in multiple sclerosis.

As with other movement disorder symptoms, the severity of a patient's tremor may wax and wane considerably over time, and is influenced by the patient's emotional state. Although the opposite may be true, generally, action tremors will be more severe during an office visit (which usually is accompanied by some uneasiness or anxiety), and tremors at rest will become less obvious or not visible at all. Thus, observations made during a short office visit may be misleading, and information from the patient (or proxy) is important.

### **Identifying Drugs and Toxins that may cause Tremor**

The list of medications and toxins that can cause tremor is long. A comprehensive history must include all medications that a patient is taking, as well as possible exposure to toxins. Table 3 summarizes the most common medications and toxins that cause tremor.

If in doubt, reports of the given drug inducing and/or exacerbating tremor should be sought. For most of these medications, tremor is a dose-dependent side effect and will disappear as the dose is decreased or the medication discontinued. In a patient who is treated with lithium or valproate sodium and who develops tremor, the serum concentrations of these substances should be determined. Some individuals may consume coffee, tea, or other stimulants in unusually high amounts, which can be a sufficient explanation for pronounced tremors. Hyperthyroidism and hypoglycemia may also cause tremor.

### **Ancillary Testing in the Assessment of tremor patients**

In the outpatient setting, the clinical features and neurologic examination findings are the most important assessment tools in evaluating patients with tremor. Extensive laboratory testing is usually not necessary. For routine evaluation, thyroid function tests are performed in most or all patients with tremor to exclude hyperthyroidism. In patients under 55 years, serum and urine tests for Wilson's Disease (WD) may be indicated. Serum ceruloplasmin as well as serum and urine copper levels can exclude WD with reasonable sensitivity, but when they give ambiguous or negative results and a clinical suspicion of WD remains, other test methods need to be considered.<sup>16-18</sup> Further studies are warranted in individual patients where a rare cause of the tremor is suspected, but these will rarely be used in the initial workup of a tremor outpatient.

## **NON-PHARMACOLOGICAL TREATMENT**

Various non-pharmacological treatment options for tremor are available, most of which are not specific for a tremor of a certain etiology.

Coping strategies form an integral part in the care of a tremor patient. Simple advice may sometimes be helpful, such as avoiding the use of a computer mouse or laser pointer which magnify tremor movements, in situations where this is embarrassing. The patient can be encouraged to inform others openly about his or her propensity to tremors and about their benign nature. Some patients may seek medical advice because of concerns that the tremor may be the first sign of a severe disorder such as PD, amyotrophic lateral sclerosis, or a brain tumor. Such patients may not need medical treatment, but feel comfortable after reassurance that their tremor does not herald a more severe disorder. Counseling should include stressing the benign natural course of a particular tremor when appropriate. Agents that are suspected to cause or worsen a tremor should be removed whenever possible.

Non-pharmacological symptomatic treatment options include the use of larger utensil handles or wrist weights, or occupational assessments and advice.<sup>19,20</sup> Positive effects of biofeedback, acupuncture, and whole body sound wave vibration therapy on tremor have been reported.<sup>21-23</sup>

## **SPECIFIC TYPES OF TREMOR**

This section describes the types of tremor that are most commonly encountered in an outpatient setting and rarer but important differential diagnoses that require specific treatment.

### **Physiological Tremor**

Slight, usually bilateral postural or kinetic action tremor, particularly in the hands and fingers, is a normal phenomenon and does not normally indicate a disorder (*physiological tremor*). Physiological tremor is more intense in situations of stress or anxiety, after strenuous physical work or exercise, or after ingestion of caffeine or other stimulants. More pronounced cases of easily visible and usually reversible tremor without evidence of neurologic disease reflect *enhanced physiological tremor*<sup>1</sup>. Usually, non-pharmacological treatment options are sufficient. However, for some patients, even mild physiologic tremor can lead to larger degrees of embarrassment and functional disability. Possible situations include a violinist at a decisive audition, or any professional giving an important presentation. The use of a beta-blocker (e.g., propranolol) before such a situation may alleviate the tremor, but the optimal dose should be found prior to the important event.

### **Essential Tremor**

Essential tremor (ET) is the most common form of tremor, and probably the most common movement disorder in general. Unfortunately, there is no uniformly accepted definition of ET. Widely used definitions are those developed by the Movement Disorder Society's Tremor Investigation Group and those used in the Washington Heights-Inwood

genetic study, but several others exist.<sup>1,24-27</sup> However, the percentage of individuals fulfilling different commonly used diagnostic criteria for ET has shown considerable variation.<sup>26</sup> The Movement Disorder Society's Tremor Investigation Group defines ET as a bilateral, largely symmetric postural or kinetic tremor involving hands and forearms that is visible and persistent, and in which there is no other explanation to the tremor.<sup>1</sup> Additional or isolated head tremor is compatible with ET as long as there is no abnormal head posturing.<sup>1</sup> In view of the difficulties in applying ET diagnostic criteria, it may be reasonable to consider treating individuals even if they do not strictly fulfill these criteria. Probably, ET reflects a clinical syndrome rather than a single disease entity.

Only about half of ET patients report a positive family history, which means that the term "familial tremor" is not congruent with ET.<sup>26</sup> ET may involve the voice, but not in isolation, and only rarely affects the legs. Although the diagnostic criteria require "largely symmetric" tremor, 50% of 487 consecutive individuals diagnosed with ET at Mayo Clinic had asymmetrical disease, most of them with greater tremor severity on their dominant side.<sup>26</sup> A tremor strictly confined to an ipsilateral arm and leg (hemibody tremor) unlikely represents ET but is usually secondary to a structural lesion.<sup>28</sup> ET usually has a frequency of 5-10 Hz and no latency to onset. Symptom severity often increases over time, but the progression can be very slow.<sup>26,29</sup> The majority of patients do not show accompanying neurological signs or symptoms, but occasionally instability or more distinct cerebellar signs may be found during examination, especially in long-standing tremor.<sup>30</sup>

Several lines of evidence suggest that cerebellar function is disturbed in ET. This is consistent with clinical observations of cerebellar signs such as slight dysmetria, an ataxic gait, or a component of intention tremor within a subgroup of patients with ET.<sup>30,31</sup> Until a few years ago, ET was considered a non-degenerative disorder resulting from abnormal excitability alone. More recently, relatively slight but distinct pathological changes in ET have been studied systematically.<sup>4</sup> Different patterns of pathological appearance were distinguishable. In one group of ET patients, there were pathological changes within the cerebellar cortex. These included the loss of Purkinje cells, rounded swellings of their axons (visible microscopically as “torpedoes”) and dendrites, a disturbed microarchitecture of the cerebellar cortex with heterotopic Purkinje cells displaced into the molecular layer, and unusually dense and tangled basket cell plexus (“hairy baskets”).<sup>4</sup> A pathologically distinct second group of ET patients had Lewy bodies in the locus ceruleus (but not in other structures, as in PD).<sup>4</sup> The noradrenergic cells of the locus ceruleus terminate in the branches of the widely ramified Purkinje cell dendrites. Purkinje cells are  $\gamma$ -amino-butyrate cells that exert an inhibitory effect on the neurons of the dentate nucleus. Cell loss in the locus ceruleus leads to decreased noradrenergic stimulation of Purkinje cells, which reduces their inhibitory effect on the dentate nucleus and the other components of the triangle of Guillain and Mollaret. This mechanism is analogous to the severe action tremor characteristic of spinocerebellar ataxia type 2 (SCA 2), whose pathological correlate is the preferential degeneration of Purkinje cells.<sup>32</sup> Efferent fibers of the cerebellar dentate nucleus also project to the ventrointermediate nucleus of thalamus (VIM). These more recent pathological findings, taken together with the higher incidence of ET observed in relatives of individuals with

other neurodegenerative disorders such as PD and possibly a common genetic background,<sup>33-35</sup> have led to suggestions that ET in fact also is a neurodegenerative disorder.

### Treatment of Essential Tremor

A variety of treatment options for ET are available today, which makes it possible but also necessary to select the most appropriate solution for the individual patient. The patient's subjective experience of the tremor's severity, and the degree of impairment and disability that it causes in the patient's life are more important than the objective assessment during the patient's clinic visit. Such assessment may be difficult. Studies have shown that on average, physical and mental quality of life measures are lower in ET patients compared to healthy individuals.<sup>36,37</sup> Nevertheless, a considerable number of ET patients have a low degree of impairment or disability and little emotional suffering from their disorder. The non-pharmacological treatment options outlined above are considered for all patients with ET.

Pharmacological treatment may be utilized either intermittently or daily and is most effective at reducing limb tremor in ET. In the absence of contraindications, propranolol or primidone are both recommended as first-line choices.<sup>15,38-40</sup> Propranolol may be effective typically in doses of 40 to 240 mg/day. It may be prudent to obtain an electrocardiogram prior to starting propranolol, to assess for significant bradycardia, and to be cognizant of a beta blocker's potential to induce orthostatic hypotension, especially in older patients. Primidone is not approved for the treatment of ET in many countries (including the U.S.A.), but widely considered effective. It should be initiated gingerly,

e.g., 12.5 mg daily, then titrated upward slowly to the lowest, effective dose, which is usually between 50 and 750mg daily (divided into bid or tid dosing). If propranolol or primidone do not provide satisfactory tremor relief, guidelines unanimously recommend the combination of propranolol plus primidone, whereas gabapentin, topiramate, or lorazepam are considered second and third line drugs.<sup>15,39,40</sup> Clozapine or botulinum toxin injections may provide relief to patients not responding to the options above, but both have disadvantages.<sup>39,41</sup> Clozapine confers a risk of agranulocytosis and necessitates checking regular blood cell counts. Botulinum toxin remains expensive, needs to be administered repeatedly, and there is a risk for weakness in the body parts treated. Overall, the pharmacological treatment efficacy of ET is unfortunately low. A reduction of the tremor's severity by 75% is considered a good response, and only 40-50% of patients will benefit from pharmacological treatment.<sup>3,38</sup> The tremor will rarely disappear completely or in all situations, and thus physician and patient need to be aware that the goal of treatment is a noticeable reduction in tremor severity, not utter freedom from symptoms. A recent study on 528 ET patients found that almost one third of patients discontinued treatment within the first year.<sup>4</sup> This fraction was similar for those with mild or more severe tremor, and the result was largely ascribed to the inadequacy of medical treatment options.<sup>4</sup>

In one study, alcohol ingestion was more efficacious at alleviating the tremor of ET than propranolol or primidone, but some patients experience a rebound worsening of tremor when the alcohol's effect wanes.<sup>42</sup> There are concerns about alcohol dependence and abuse, but studies addressing this issue have led to conflicting results.<sup>15</sup> Alcohol may not be acceptable to a patient for personal, cultural or religious reasons. Surgical treatment

with deep brain stimulation (DBS) of a target within or near the VIM (Figure 1) can improve ET in patients who do not respond satisfactorily to other treatment modalities and has a good short-term and long term effect.<sup>43</sup> Maximal motor improvement of motor symptoms and minimal side effects were achieved by targeting DBS at the cerebellothalamic tracts in the subthalamic area rather than the thalamus itself.<sup>44</sup>

### **Tremor in Parkinson Disease**

Tremor is one of the cardinal features of PD and was already described in ancient Indian descriptions of the “kampavata” illness, which probably corresponds to the modern definition of PD.<sup>45</sup> Tremor is often the presenting feature of PD, but it is not a necessary feature for this diagnosis, and about 25% of patients with PD in fact never develop tremor (akineti-rigid form). Furthermore, tremor may diminish in later stages of the disease, when bradykinesia becomes more prominent.<sup>46</sup> The typical and rather complex movements of parkinsonian rest tremor (Figure 2) indicate PD with high specificity. They include agonist and antagonist activation alternating in a precisely tuned manner, often leading to a stereotypical series of movements such as the typical pill rolling tremor. There are descriptions of patients with only a rest tremor who do not subsequently develop PD, and the term *monosymptomatic rest tremor* has been suggested when this situation has persisted for at least two years.<sup>1</sup> However, a reduced putaminal fluorodopa uptake has been found in some patients with monosymptomatic rest tremor, suggesting they may have subclinical parkinsonian syndromes.<sup>47</sup>

Diagnostic difficulties can arise when a patient only has tremor and no other signs and symptoms are found, when no tremor is visible during the office visit, or when other

forms of tremor coexist.<sup>1</sup> Rarely, PD patients may only have a kinetic tremor. Thus, a diagnosis of PD should never be based solely on tremor, but requires the presence of the other cardinal symptoms of PD, notably, bradykinesia.

Tremor in PD is often more difficult to alleviate than the hypokinetic PD manifestations (bradykinesia and rigidity).<sup>48</sup> The tremor is not as responsive to dopaminergic therapy as the hypokinesias, or may not improve with medical treatment at all.<sup>48</sup> An analysis of what is known about the pathogenesis of PD tremor may help explain this discrepancy. The pathological hallmark of PD is the loss of dopamine-producing neurons in the substantia nigra pars compacta (SNc), especially its ventrolateral portion, which projects to the putamen.<sup>48,49</sup> This induces a dopaminergic deficit in the striatum, where these neurons form synapses on neurons belonging to two distinct classical cortico-striatal-thalamo-cortical circuits, known as the indirect and direct pathways (Figure 1). Dopaminergic neurons project to striatal cells that form part of the indirect pathway. These are equipped with inhibitory D<sub>2</sub> receptors. Dopamine also acts on the excitatory D<sub>1</sub> receptors found on inhibitory striatopallidal pathway cells of the indirect pathway. Thus, dopamine exerts an inhibitory net effect on the indirect pathway loop, and the dopaminergic deficit of PD reduces this inhibition. More recent findings also show that the anatomical connections between the brainstem nuclei are more complex than previously appreciated. Cortical neurons that activate the STN without any relay in the basal ganglia have been identified, the hyperdirect pathway.<sup>50,51</sup> Furthermore, the “striatofugal” neurons from the striatum to the internal globus pallidus (GPi) which form part of the classical direct pathway, at least in non-human primates also send collaterals to the external globus pallidus (GPe).<sup>52,53</sup> This means that the classical direct and indirect pathways are closely interwoven.

Furthermore, feedback neurons from the GPe to the striatum as well as from GPe to GPi have been discovered in different mammals.<sup>54</sup>

Several intriguing findings argue against the striatonigral dopaminergic deficit directly causing PD tremor. The extent of dopamine deficiency and the degree of disease progression correlate well with the severity of rigidity and bradykinesia, but not with tremor.<sup>54-56</sup> In statistical analyses of PD patients' symptoms, tremor occurred independently from the other cardinal features.<sup>57</sup> Through DBS electrodes, high frequency oscillations were recorded from the STN in PD patients with tremor, and, likewise, these oscillations correlated with akinesia and rigidity but not with tremor.<sup>56,58</sup> Rigidity and bradykinesia improved after the injection of GABA agonist muscimol into the pallidum, but simultaneously rest tremor deteriorated.<sup>59</sup> In view of these findings, it has been postulated that tremor in PD results from a compensatory mechanism downstream of the disturbed basal ganglia activity.<sup>54</sup> Another possibility is that tremor, analogous to many other signs and symptoms of PD,<sup>60</sup> may be another consequence of the neurodegenerative changes that underlie PD, independent from the direct cause of bradykinesia or rigidity.

#### Treatment of Tremor in Parkinson Disease

Available treatment options include dopaminergic agents, anticholinergics, beta blockers, and deep brain stimulation. Levodopa and dopamine agonists alleviate parkinsonian symptoms, including tremor in some patients, but often, tremor control is not satisfactory. Although frequently discussed, there is no convincing data showing that dopamine agonists lead to greater improvement of tremor than levodopa. The clinical trials that

were performed with this question in mind either did not directly compare a dopamine agonist to levodopa,<sup>61-65</sup> did not assess tremor as primary outcome but in post hoc analyses,<sup>62,65</sup> or the recorded effect sizes, even though statistically significant, were small.<sup>63,64</sup> It also remains uncertain whether the addition of a dopamine agonist to levodopa may lead to small improvements in tremor. In general, levodopa remains the antiparkinsonian medication producing maximal motor benefit in PD patients, with the fewest side effects. In patients younger than 60 years of age, dopamine agonists may be considered as there is some evidence for a possibly lower risk for dyskinesias in later stages of the disease, compared to when treatment was initiated with levodopa.<sup>66</sup> More recently, ten year follow-up data from a multicenter cohort found no such difference.<sup>67</sup> Beta-blockers have a documented effect also in parkinsonian tremor, but may increase the orthostatic hypotension that often develops in PD, which can have serious consequences. However, in 2003 a Cochrane Database systematic review of 4 studies could not determine whether beta-blocker therapy is effective and safe for the treatment of tremor in PD and warned against bradykinesias as a side effect.<sup>68</sup> Anticholinergic drugs were formerly used for the treatment of PD. The rationale behind their use is that the dopaminergic deficit in PD leads to a relative excess of acetyl choline in the striatum, and that anticholinergic drugs can restore a balance on a lower level of both transmitters. In fact, experience shows that anticholinergics can improve tremor in PD. However, there are no modern studies on their use and side effects can be dramatic. Nevertheless, some authorities recommend anticholinergics as one of several treatment options for younger patients with tremor-dominant PD who did not respond to other

medications.<sup>69</sup> DBS targeting the subthalamic nucleus or VIM, stations in the indirect pathway, has been shown to be effective.<sup>70,71</sup>

### **Other Causes of Tremor**

Many other disorders may be encountered in an outpatient clinical practice that can cause tremor or movement disorders with a similar appearance.

### **Neuropathic Tremor**

Tremor can be a presenting or predominant sign of polyneuropathies or other lesions of peripheral nerves (neuropathic tremor). In particular, immunoglobulin-mediated forms, such as IgM-neuropathy or chronic inflammatory demyelinating polyneuropathy, may be associated with tremor. Usually, these disorders develop subacutely within weeks to months, thus, the temporal profile of tremor development is unique. On the neurological examination, other signs of peripheral neuropathy will be present. Serum electrophoresis, electrophysiological studies, cerebrospinal fluid analysis, and, sometimes, nerve biopsy, can help establish a diagnosis.<sup>72</sup> These disorders need to be diagnosed in a timely manner as they may be treatable with immunosuppressive therapies, such as corticosteroids, intravenous immunoglobulin, cyclophosphamid or plasma exchange. The cause of excessive immunoglobulin production is usually monoclonal gammopathy of unknown significance, but a certain amount of screening tests is usually conducted to exclude plasmacytoma, amyloidosis, or lymphoreticular malignancy.<sup>73</sup>

### **Tremor from cerebral or brainstem syndromes**

Lesions of cerebral structures implicated in tremorogenesis (Figure 1) may cause tremor. The lesions may be a consequence of trauma, stroke, tumors, infection, or other disorders. The history and temporal development can provide clues, as these tremors develop within a shorter time.<sup>74</sup> Treatment of the underlying disorder is paramount. Symptomatic treatments of the tremor include similar options as for other types of tremor. **Holmes' Tremor (midbrain tremor, rubral tremor, cerebellar outflow tremor)** has an unusual appearance of combined rest and intention tremor, often localized to one upper extremity, associated with ipsilateral dysmetria and dysdiadochokinesia.<sup>6</sup> Some patients may have postural tremor, often primarily in proximal muscles, as an additional feature.<sup>1</sup> The frequency is generally below 4.5 Hz and may be irregular. Holmes' tremor occurs as a consequence of a lesion damaging both the dopaminergic and the cerebellothalamic/cerebelloolivary systems.<sup>6,75</sup> It does not appear simultaneously with the lesion, but after a delay of 1 to 24 months. Brainstem stroke or trauma are the most common causes. As the dopaminergic system is involved in most cases, treatment with levodopa should be attempted.<sup>75</sup> Drugs used for the treatment of ET may also be effective, and DBS in VIM has proven beneficial.<sup>6</sup>

### **Dystonic Tremor**

Dystonic tremor is a focal and mainly postural/kinetic tremor in an individual with dystonia. The tremor may occur in the same body part as the dystonia, or in different areas. Both the frequency and amplitude are often irregular and variable. A typical example is dystonic head tremor in a patient with torticollis. Diagnosis rests on finding other signs or symptoms of dystonia, bearing in mind that some symptoms, such as mild

blepharospasm, a subtle voice change of spasmodic dysphonia, or a slight torticollis, may be easily missed as important clues by both the physician and the patient. Responsiveness to sensory tricks (*gestes antagonistiques*) indicates a dystonic tremor. Many dystonias are hereditary, and signs and symptoms of dystonia in a relative may help establish a correct diagnosis. The precise relationship of dystonic tremor to dystonia has been debated. It has been suggested that dystonic movements may be tremulous in nature, or that dystonic tremor results from a more or less conscious attempt of the patient to restore normal body position against the permanent dystonic muscle contraction<sup>6</sup>. No intrinsic oscillatory rhythm has been found or proposed, in line with the lack of rhythmicity generally observed in dystonic tremor. In dystonia, activity in the lentiform nuclei (putamen, external and internal globus pallidus) at rest is generally disturbed, and there are cortical abnormalities in areas of the sensorimotor circuitry.<sup>76</sup> Botulinum toxin injections can ameliorate dystonia and dystonic tremor and are accepted as the treatment of choice.<sup>39</sup> In patients where botulinum toxin is insufficient or impracticable, dystonic tremor can be treated with functional lesioning of the common outflow from the basal ganglia through the GPi and VIM, e.g. by deep brain stimulation.<sup>77</sup> **Task-specific tremor**, such as tremor that only occurs when writing (primary writing tremor) or when performing other specific tasks, may be a form of dystonic tremor.<sup>78</sup>

### **Psychogenic Tremor**

As most other movement disorder signs, tremor or tremor-like movements may have a psychogenic cause. Differentiating psychogenic tremor from tremor that has a somatic etiology can be very challenging, and misdiagnosis is not uncommon. These difficulties

arise because the spectrum of somatic tremor types is wide and as their symptoms usually fluctuate in severity, depending on the subject's emotional state among other factors. Several clues may suggest a psychogenic cause.<sup>79,80</sup> Sudden onset, spontaneous remission, or larger variations of amplitude and frequency are unusual in somatic tremor. A psychogenic tremor may become less severe or disappear on distraction, for example with alternate finger tapping or mental concentration on serial 7s, or on suggestion, for example by applying a vibrating tuning fork to a patient's forehead and informing the patient (wrongly) that this can stop the tremor. Similar information about hyperventilation may lead to tremor exacerbation.<sup>80</sup> Entrainment refers to the change in frequency of a psychogenic tremor in adaptation to voluntary movements, such as a regular movement in the contralateral limb (Figure 3). Loading a tremorous limb with a weight changes the tremor frequency in physiological and enhanced physiological tremor and ET but not in psychogenic tremor,<sup>6</sup> and may in fact lead to an increase in amplitude of a psychogenic tremor.<sup>81</sup>

### **Intention Tremor**

Intention tremor results when the antagonist activation which normally stops a goal-directed movement as the goal is approached, is inappropriately sized or timed. It often indicates a lesion in the dentate nucleus or its outflow tract through the superior cerebellar peduncle. Underlying causes include multiple sclerosis, spinocerebellar ataxias, and other degenerative, metabolic, or neoplastic disorders affecting these cerebellar structures. Treatment is often not satisfactory, but low doses of

benzodiazepines can improve the situation, and promising results of DBS treatment have been reported.<sup>82</sup>

### **Tremor in Wilson's Disease**

All types of tremor can be the presenting sign of **Wilson's disease (WD)**, with postural and/or rest tremor being most common. The typical proximal “wing beating tremor” is often missing in the early stages of the disease. Also, the other features of the clinical phenotype can vary greatly.<sup>18</sup> Dysarthria and subtle personality changes are early signs in about half of patients, whereas the more well known corneal Kayser-Fleischer and MRI changes can be difficult to detect or absent.<sup>17</sup> The disease is rare and follows an autosomal recessive pattern of inheritance. More than 150 different mutations have been described in the *ATP7B* gene responsible for WD. Unfortunately, a normal serum ceruplasmin level does not rule out Wilson's disease with certainty, and given the potential for causative treatment, at least one more means of investigation such as elevated 24-hour copper urine should probably be obtained if ceruplasmin is normal.<sup>16</sup> A molecular genetic diagnosis is most sensitive, but is a laborious and costly effort as the known mutations are spread out over the gene's 21 exons.

### **Primary Orthostatic Tremor**

Primary orthostatic tremor has a peculiar and highly characteristic clinical picture with high frequency (12-18Hz) tremor that occurs in the legs of a person when erect and causes postural instability. The high tremor frequency leads to a partial fusion of the single muscle contractions, and it can be easier to hear the contractions through a

stethoscope applied to thigh or calf muscles. The sound has been compared to that of a helicopter.<sup>83</sup> Treatment options include clonazepam, primidone,<sup>84</sup> benzodiazepines, and gabapentin.<sup>85</sup>

### **Palatal Tremor**

Palatal tremor mainly affects the soft palate but may include other cranial musculature.<sup>13</sup>

It can be caused by a lesion in the brainstem, e.g. through infarction, hemorrhage, or trauma, that affects the rostral parts of the triangle of Guillain and Mollaret.<sup>86</sup> In other patients, the cause remains enigmatic. Olivary hypertrophy results from a degenerative process and can be detected in magnetic resonance imaging. Patients can be unimpaired by the tremor, but may experience a disturbing clicking sound generated by activation of muscles in proximity of the Eustachian tube.<sup>13</sup>

### **CONCLUSION**

Tremor can be a complaint or sign indicating various underlying neurological disorders. Progress has been made regarding our understanding of its pathophysiology and the available options to treat tremor patient have increased. Nevertheless, important questions remain unanswered, such as the exact cause or origin of tremors. There clearly is a need for more effective treatments for most forms of tremor, or the underlying neurological disorders that cause tremor.

## Acknowledgements

We thank Jay A. Van Gerpen, Department for Neurology, Mayo Clinic, for providing the images and patient descriptions for Figure 2 and 3, and for revising the manuscript, Margaret A. McKinney, Media Support Services, Mayo Clinic, for the graphic design of Figure 1, and Meinie Seelen, Lund University, Sweden, for proofreading the manuscript. AP received funding from Swedish Parkinson Academy, The Research Foundation of the Swedish Parkinson's Disease Association, Lund University Research Fund, and The Royal Physiographic Society in Lund.

ZKW is partially supported by the NS40256, NS057567, AG017216, NS070276, Mayo Clinic Florida Research Committee CR program, and the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch.

## References

1. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. *Mov Disord.* 1998;13 Suppl 3:2-23.
2. Zesiewicz TA, Hauser RA. Phenomenology and treatment of tremor disorders. *Neurol Clin.* Aug 2001;19(3):651-680, vii.
3. Thanvi B, Lo N, Robinson T. Essential tremor-the most common movement disorder in older people. *Age Ageing.* Jul 2006;35(4):344-349.
4. Louis ED. Essential tremor: evolving clinicopathological concepts in an era of intensive post-mortem enquiry. *Lancet Neurol.* May 5 2010;9:613-622.

5. Louis ED, Rios E. Embarrassment in essential tremor: prevalence, clinical correlates and therapeutic implications. *Parkinsonism Relat Disord.* Aug 2009;15(7):535-538.
6. Elble R. The Pathophysiology of Tremor. In: Watts RL, Koller WC, eds. *Movement Disorders: Neurologic Principles and Practice*. 2 ed. New York: McGraw Hill; 2004:481-492.
7. Van Der Giessen RS, Koekkoek SK, van Dorp S, et al. Role of olivary electrical coupling in cerebellar motor learning. *Neuron.* May 22 2008;58(4):599-612.
8. Llinas R, Yarom Y. Oscillatory properties of guinea-pig inferior olivary neurones and their pharmacological modulation: an in vitro study. *J Physiol.* Jul 1986;376:163-182.
9. Monsef HR, Ghobadi A, Iranshahi M, Abdollahi M. Antinociceptive effects of Peganum harmala L. alkaloid extract on mouse formalin test. *J Pharm Pharm Sci.* Feb 19 2004;7(1):65-69.
10. Frison G, Favretto D, Zancanaro F, Fazzin G, Ferrara SD. A case of beta-carboline alkaloid intoxication following ingestion of Peganum harmala seed extract. *Forensic Sci Int.* Aug 6 2008;179(2-3):e37-43.
11. Miwa H, Hama K, Kajimoto Y, Kondo T. Effects of zonisamide on experimental tremors in rats. *Parkinsonism Relat Disord.* 2008;14(1):33-36.
12. Wilms H, Sievers J, Deuschl G. Animal models of tremor. *Mov Disord.* Jul 1999;14(4):557-571.
13. Goyal M, Versnick E, Tuite P, et al. Hypertrophic olivary degeneration: metaanalysis of the temporal evolution of MR findings. *AJNR Am J Neuroradiol.* Jun-Jul 2000;21(6):1073-1077.

14. Samuel M, Torun N, Tuite PJ, Sharpe JA, Lang AE. Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. *Brain*. Jun 2004;127(Pt 6):1252-1268.
15. Hess CW, Saunders-Pullman R. Movement disorders and alcohol misuse. *Addict Biol*. Jun 2006;11(2):117-125.
16. Pfeiffer RF. Wilson's Disease. *Semin Neurol*. Apr 2007;27(2):123-132.
17. Ghika J, Vingerhoets F, Maeder P, Borruat F-X, Bogousslavsky J. Maladie de Wilson. *EMC-Neurologie*. 2004;1:481-511.
18. Mak CM, Lam CW. Diagnosis of Wilson's disease: a comprehensive review. *Crit Rev Clin Lab Sci*. 2008;45(3):263-290.
19. Meshack RP, Norman KE. A randomized controlled trial of the effects of weights on amplitude and frequency of postural hand tremor in people with Parkinson's disease. *Clin Rehabil*. Aug 2002;16(5):481-492.
20. McGruder J, Cors D, Tiernan AM, Tomlin G. Weighted wrist cuffs for tremor reduction during eating in adults with static brain lesions. *Am J Occup Ther*. Sep-Oct 2003;57(5):507-516.
21. Lundervold DA, Poppen R. Biobehavioral intervention for older adults coping with essential tremor. *Appl Psychophysiol Biofeedback*. Mar 2004;29(1):63-73.
22. Shulman LM, Wen X, Weiner WJ, et al. Acupuncture therapy for the symptoms of Parkinson's disease. *Mov Disord*. Jul 2002;17(4):799-802.
23. King LK, Almeida QJ, Ahonen H. Short-term effects of vibration therapy on motor impairments in Parkinson's disease. *NeuroRehabilitation*. 2009;25(4):297-306.

24. Louis ED, Ottman R, Ford B, et al. The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research. *Neuroepidemiology*. 1997;16(3):124-133.
25. Jankovic J, Beach J, Pandolfo M, Patel PI. Familial essential tremor in 4 kindreds. Prospects for genetic mapping. *Arch Neurol*. Mar 1997;54(3):289-294.
26. Whaley NR, Putzke JD, Baba Y, Wszolek ZK, Uitti RJ. Essential tremor: phenotypic expression in a clinical cohort. *Parkinsonism Relat Disord*. Aug 2007;13(6):333-339.
27. Deuschl G, Elble R. Essential tremor--neurodegenerative or nondegenerative disease towards a working definition of ET. *Mov Disord*. Oct 30 2009;24(14):2033-2041.
28. Benito-Leon J, Louis ED. Essential tremor: emerging views of a common disorder. *Nat Clin Pract Neurol*. Dec 2006;2(12):666-678; quiz 662p following 691.
29. Putzke JD, Whaley NR, Baba Y, Wszolek ZK, Uitti RJ. Essential tremor: predictors of disease progression in a clinical cohort. *J Neurol Neurosurg Psychiatry*. Nov 2006;77(11):1235-1237.
30. Singer C, Sanchez-Ramos J, Weiner WJ. Gait abnormality in essential tremor. *Mov Disord*. Mar 1994;9(2):193-196.
31. Deuschl G, Wenzelburger R, Loffler K, Raethjen J, Stolze H. Essential tremor and cerebellar dysfunction clinical and kinematic analysis of intention tremor. *Brain*. Aug 2000;123 ( Pt 8):1568-1580.
32. Lastres-Becker I, Rub U, Auburger G. Spinocerebellar ataxia 2 (SCA2). *Cerebellum*. 2008;7(2):115-124.

33. Spanaki C, Plaitakis A. Essential tremor in Parkinson's disease kindreds from a population of similar genetic background. *Mov Disord.* Aug 15 2009;24(11):1662-1668.
34. Vilarino-Guell C, Ross OA, Wider C, et al. LINGO1 rs9652490 is associated with essential tremor and Parkinson disease. *Parkinsonism Relat Disord.* Feb;16(2):109-111.
35. Vilarino-Guell C, Wider C, Ross OA, et al. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. *Neurogenetics.* Apr 6.
36. Lorenz D, Schwieger D, Moises H, Deuschl G. Quality of life and personality in essential tremor patients. *Mov Disord.* Aug 2006;21(8):1114-1118.
37. Nguyen HV, Ngian V, Cordato D, Shen Q, Chan DK. Quality of life in a random sample of community dwelling older patients with essential tremor. *Acta Neurol Scand.* Nov 2007;116(5):289-292.
38. Lyons KE, Pahwa R. Pharmacotherapy of essential tremor : an overview of existing and upcoming agents. *CNS Drugs.* 2008;22(12):1037-1045.
39. Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology.* Jun 28 2005;64(12):2008-2020.
40. Elble RJ. Tremor: clinical features, pathophysiology, and treatment. *Neurol Clin.* Aug 2009;27(3):679-695, v-vi.
41. Simpson DM, Blitzer A, Brashear A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the

Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Vol 70; 2008:1699-1706.

42. Bain PG, Findley LJ, Thompson PD, et al. A study of hereditary essential tremor. *Brain*. Aug 1994;117 ( Pt 4):805-824.
43. Rehncrona S, Johnels B, Widner H, Tornqvist AL, Hariz M, Sydow O. Long-term efficacy of thalamic deep brain stimulation for tremor: double-blind assessments. *Mov Disord*. Feb 2003;18(2):163-170.
44. Herzog J, Hamel W, Wenzelburger R, et al. Kinematic analysis of thalamic versus subthalamic neurostimulation in postural and intention tremor. *Brain*. Jun 2007;130(Pt 6):1608-1625.
45. Gourie-Devi M, Ramu MG, Venkataram BS. Treatment of Parkinson's disease in 'Ayurveda' (ancient Indian system of medicine): discussion paper. *J R Soc Med*. Aug 1991;84(8):491-492.
46. Elizan TS, Sroka H, Maker H, Smith H, Yahr MD. Dementia in idiopathic Parkinson's disease. Variables associated with its occurrence in 203 patients. *J Neural Transm*. 1986;65(3-4):285-302.
47. Brooks DJ, Playford ED, Ibanez V, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. *Neurology*. Aug 1992;42(8):1554-1560.
48. Carr J. Tremor in Parkinson's disease. *Parkinsonism Relat Disord*. Mar 2002;8(4):223-234.
49. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. *Lancet Neurol*. Dec 2009;8(12):1150-1157.

50. Nambu A, Tokuno H, Takada M. Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. *Neurosci Res.* Jun 2002;43(2):111-117.
51. Nambu A. A new approach to understand the pathophysiology of Parkinson's disease. *J Neurol.* Oct 2005;252 Suppl 4:IV1-IV4.
52. Levesque M, Parent A. The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. *Proc Natl Acad Sci U S A.* Aug 16 2005;102(33):11888-11893.
53. Nadjar A, Brotchie JM, Guigoni C, et al. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. *J Neurosci.* Aug 23 2006;26(34):8653-8661.
54. Zaidel A, Arkadir D, Israel Z, Bergman H. Akineto-rigid vs. tremor syndromes in Parkinsonism. *Curr Opin Neurol.* Aug 2009;22(4):387-393.
55. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? *Ann Neurol.* Jan 1997;41(1):58-64.
56. Weinberger M, Hutchison WD, Dostrovsky JO. Pathological subthalamic nucleus oscillations in PD: can they be the cause of bradykinesia and akinesia? *Exp Neurol.* Sep 2009;219(1):58-61.
57. Stochl J, Boomsma A, Ruzicka E, Brozova H, Blahus P. On the structure of motor symptoms of Parkinson's disease. *Mov Disord.* Jul 15 2008;23(9):1307-1312.
58. Kuhn AA, Tsui A, Aziz T, et al. Pathological synchronisation in the subthalamic nucleus of patients with Parkinson's disease relates to both bradykinesia and rigidity. *Exp Neurol.* Feb 2009;215(2):380-387.

59. Penn RD, Kroin JS, Reinkensmeyer A, Corcos DM. Injection of GABA-agonist into globus pallidus in patient with Parkinson's disease. *Lancet*. Jan 31 1998;351(9099):340-341.
60. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. *Ann Neurol*. Apr 2006;59(4):591-596.
61. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. *J Neurol Neurosurg Psychiatry*. Jun 2002;72(6):713-720.
62. Schrag A, Keens J, Warner J. Ropinirole for the treatment of tremor in early Parkinson's disease. *Eur J Neurol*. May 2002;9(3):253-257.
63. Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease. *Mov Disord*. Feb 2003;18(2):176-180.
64. Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. *Mov Disord*. Nov 2003;18(11):1324-1331.
65. Moller JC, Eggert KM, Unger M, Odin P, Chaudhuri KR, Oertel WH. Clinical risk-benefit assessment of dopamine agonists. *Eur J Neurol*. Sep 2008;15 Suppl 2:15-23.
66. van Hilten JJ, Ramaker CC, Stowe R, Ives NJ. Bromocriptine versus levodopa in early Parkinson's disease. *Cochrane Database Syst Rev*. 2007(4):CD002258.

67. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. *Neurology*. Aug 12 2008;71(7):474-480.
68. Crosby NJ, Deane KH, Clarke CE. Beta-blocker therapy for tremor in Parkinson's disease. *Cochrane Database Syst Rev*. 2003(1):CD003361.
69. Segrell ND, Granérus A-K, Holmberg B, et al. [Swedish Guidelines for the Diagnosis and Treatment of Parkinson's Disease]. Revised version #3 ed; 2009.
70. Krack P, Pollak P, Limousin P, Benazzouz A, Benabid AL. Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease. *Lancet*. Dec 6 1997;350(9092):1675.
71. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. *N Engl J Med*. Jun 3;362(22):2077-2091.
72. Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. *N Engl J Med*. Mar 31 2005;352(13):1343-1356.
73. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. *N Engl J Med*. May 28 1998;338(22):1601-1607.
74. Netravathi M, Pal PK, Ravishankar S, Indira Devi B. Electrophysiological evaluation of tremors secondary to space occupying lesions and trauma: correlation with nature and sites of lesions. *Parkinsonism Relat Disord*. Jan;16(1):36-41.
75. Gajos A, Bogucki A, Schinwelski M, et al. The clinical and neuroimaging studies in Holmes tremor. *Acta Neurol Scand*. Jan 15.
76. Breakefield XO, Blood AJ, Li Y, Hallett M, Hanson PI, Standaert DG. The pathophysiological basis of dystonias. *Nat Rev Neurosci*. Mar 2008;9(3):222-234.

77. Ostrem JL, Starr PA. Treatment of dystonia with deep brain stimulation. *Neurotherapeutics*. Apr 2008;5(2):320-330.
78. Bain PG, Findley LJ, Britton TC, et al. Primary writing tremor. *Brain*. Dec 1995;118 ( Pt 6):1461-1472.
79. Bhidayasiri R. Differential diagnosis of common tremor syndromes. *Postgrad Med J*. Dec 2005;81(962):756-762.
80. Kenney C, Diamond A, Mejia N, Davidson A, Hunter C, Jankovic J. Distinguishing psychogenic and essential tremor. *J Neurol Sci*. Dec 15 2007;263(1-2):94-99.
81. Deuschl G, Koster B, Lucking CH, Scheidt C. Diagnostic and pathophysiological aspects of psychogenic tremors. *Mov Disord*. Mar 1998;13(2):294-302.
82. Freund HJ, Barnikol UB, Nolte D, et al. Subthalamic-thalamic DBS in a case with spinocerebellar ataxia type 2 and severe tremor-A unusual clinical benefit. *Mov Disord*. Apr 15 2007;22(5):732-735.
83. Brown P. New clinical sign for orthostatic tremor. *Lancet*. Jul 29 1995;346(8970):306-307.
84. Britton TC, Thompson PD, van der Kamp W, et al. Primary orthostatic tremor: further observations in six cases. *J Neurol*. Apr 1992;239(4):209-217.
85. Raethjen J, Deuschl G. [Tremor]. *Ther Umsch*. Jan 2007;64(1):35-40.
86. Sharma P, Eesa M, Poppe AY, Goyal M. Teaching NeuroImage: posttraumatic palatal tremor. *Neurology*. Sep 23 2008;71(13):e30.
87. Raethjen J, Kopper F, Govindan RB, Volkmann J, Deuschl G. Two different pathogenetic mechanisms in psychogenic tremor. *Neurology*. Sep 14 2004;63(5):812-815.

## Figure Captions

**Figure 1: Schematic and simplified synopsis of the brain regions and pathways involved in tremorogenesis. See text for details.**

Abbreviations: D<sub>1</sub>, Dopamine receptor type 1; D<sub>2</sub>, Dopamine receptor type 2; exc., excitatory; GABA,  $\gamma$ -amino butyric acid; Glu, glutamate; GPe, external globus pallidus; GPi, internal globus pallidus; ICP, inferior cerebellar peduncle; inh., inhibitory; SCP, superior cerebellar peduncle; SNc, substantia nigra, pars compacta; SNr, substantia nigra pars reticulata; STN, subthalamic nucleus; VIM, ventrointermediate nucleus of thalamus.

**Figure 2: Electrophysiological surface recording study. Complex nature of tremor at rest in PD.**

The surface electromyography (EMG) recordings of a 67 year old man with Parkinson disease reveal a rhythmic activity with a frequency of about 5 Hz in all muscles studied. All recordings shown were performed simultaneously. The antagonists, anterior tibial and gastrocnemius muscles, are activated in shifted phases, and a slight electrical activity was detected in the quadriceps musculature on the same side. The frequency in the electrophysiological activity on the left and on the right side differs slightly, with thirteen activations in the left anterior tibial muscle but only twelve in the right side during the period of time represented in the figure. This indicates that tremors originate in separate circuits in the left and right sides, and the overall picture underscores the central origin and complex nature of Parkinsonian tremor.

**Figure 3: Electrophysiological surface recording study. Entrainment of psychogenic tremor.**

A 28 year old female had developed tremor in her legs 3 months previously. The surface EMG recordings shown here were recorded with the patient standing. There is a nearly simultaneous and rhythmic activity in both anterior tibial muscles, but the length, amplitude and shape of the single bursts is less regular than in Figure 2. Utterly simultaneous contractions in both limbs (upper row) often indicate voluntary activation<sup>87</sup>. There is only a very slight antagonist activity simultaneous with a reflex-like tonic activity in all muscles. When the patient was asked to slowly tap down her right foot (lower row, black bar), the rhythmic activity almost completely abates (entrainment), suggesting a psychogenic cause for this patient's tremor.

**Table 1: Parameters for the clinical characterization of tremor**

- Tremor at rest / Action tremor
- Location (affected body part)
- Frequency
- Rhythmicity
- Amplitude
- Exacerbating or alleviating factors
- Other neurological signs or symptoms

## Table 2. Tremor types

**Rest tremor (tremor at rest):** Tremor in a body part that is not voluntarily activated and is completely supported against gravity (includes re-emerging tremor, see text).

**Action tremor:** Any tremor that is produced by voluntary contraction of muscle.

**Postural tremor:** Tremor that is present while voluntarily maintaining a position against gravity. Rarely, the tremor may specifically occur in certain positions, but not in others (position-specific tremor).

**Kinetic tremor:** Tremor that occurs during any voluntary movement.

- **Unspecified kinetic tremor:** during non-goal-directed movements.
- **Intention tremor:** during goal-directed movements.
- **Task-specific kinetic tremor:** appears only, or becomes markedly exacerbated, during specific activities.
- **Isometric tremor:** occurs as a result of muscle contraction against a rigid stationary object.


Adapted from: Bhidayasiri R. Differential diagnosis of common tremor syndromes.

*Postgrad Med J.* Dec 2005;81(962):756-762, with permission from BMJ Publishing Group Ltd.

**Table 3**

**Common Causes of Medication- or Toxin-induced Tremors**


- **Beta-adrenergic agonists:** terbutaline, metaproterenol, isoetharine, epinephrine (adrenaline)
- **Drugs used in psychiatry:** most antidepressants, lithium, neuroleptics
- **Anticonvulsants:** valproate sodium
- **Dopamine agonists:** amphetamine
- **Heavy metals:** mercury, lead, arsenic, bismuth
- **Xanthines or derivatives:** coffee, tea, theophylline




**R Quadriceps**



**R Tib. Ant.**



**R Gastr.**





**L. Tib. Ant.**



**100ms**

A solid black horizontal bar located at the bottom right of the image, used as a scale for the time axis.



*Right Foot Tap*

100ms